# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k110736   
B. Purpose for Submission: New device   
C. Measurand: Ferritin   
D. Type of Test: Quantitative, immuno-turbidimetric

E. Applicant: Siemens Healthcare Diagnostics, Inc.

F. Proprietary and Established Names: ADVIA® 1650 Chemistry Ferritin (FRT) Reagent ADVIA® Chemistry Liquid Specific Protein Calibrator

# G. Regulatory Information:

1. Regulation section: 21 CFR $\ S 8 6 6 . 5 3 4 0$ Ferritin immunological test system 21 CFR $\ S 8 6 2 . 1 1 5 0 $ Calibrator

2. Classification: Class II

3. Product code: DBF: Ferritin, antigen, antiserum, control JIX: Calibrator, multi-analyte mixture

4. Panel: Immunology (82) Clinical Chemistry (75)

# H. Intended Use:

1. Intended use(s): The ADVIA® 1650 Chemistry Ferritin (FRT) Reagent: For in vitro diagnostic use in the quantitative determination of ferritin in human serum and plasma on the ADVIA® 1650 Chemistry system. Measurements of ferritin aid in the diagnosis of diseases affecting iron metabolism, such as hemochromatosis (iron overload) and iron deficiency anemia.

The ADVIA® Chemistry Liquid Specific Protein Calibrators: For in vitro diagnostic use in the calibration of ADVIA® Chemistry systems for the Alpha-AcidGlycoprotein (AAG), Alpha-1-Antitrypsin (AAT), Anti-streptolysin-O_2 (ASO_2), Complement C3 (C3), Complement C4 (C4), Ferritin (FRT), Haptoglobin (HAPT), Immunoglobulin A_2 (IGA_2), Immunoglobulin G_2 (IGG_2), Immunoglobulin M_2 (IGM_2), Prealbumin (PREALB), Rheumatoid Factor (RF), and Transferrin (TRF) methods.

2. Indication(s) for use: Same as Intended Use.

3. Special conditions for use statement(s):

Prescription use only.

4. Special instrument requirements: ADVIA® 1650 Chemistry system (k990346)

# I. Device Description:

The ADVIA® 1650 Chemistry Ferritin reagents are ready-to-use liquid reagents. They are supplied in two different package sizes, 200 or 800 tests per wedge with 4 wedges per kit.

There are two reagents. Reagent I consists of glycine buffer, $\mathsf { p H } 8 . 3$ (170mmol/L), sodium chloride $\mathrm { 1 0 0 m m o l / L ) }$ , bovine serum albumin $( 0 . 5 \% )$ and sodium azide $( 0 . 0 9 \% )$ . Reagent 2 contains latex particles coated with rabbit anti-ferritin antibodies, glycine buffer, $\mathrm { p H } 7 . 3$ (170 mmols/L), sodium chloride (100 mmols/L), bovine serum albumin $( 0 . 1 \% )$ and sodium azide $( 0 . 0 9 \% )$ .

ADVIA® Chemistry Liquid Specific Protein Calibrator is a multi-analyte, liquid, human serum based product containing multiple analytes. They are supplied as ready-to-use $1 . 0 { \cdot } \mathrm { m L }$ solutions in 6 vials, one for each of 6 calibrator levels. The low level (Level 1) is a zero-level calibrator with no analytes present in the formulation. The target ferritin concentrations of Levels 2 – 6 are 25, 50, 100, 225 and $4 7 5 \mathrm { m g / d L }$ . All analytes except ferritin and C-reactive protein (CRP) were cleared previously in k103701. There are no changes to the existing products except the addition of ferritin value assignment process and the addition of the ferritin analyte to the intended use of the device.

The recommended controls are three serum pools previously cleared in k992550

# J. Substantial Equivalence Information:

1. Predicate device name(s) and predicate K number(s): N Latex Ferritin reagent (k993273) Randox Liquid Protein Calibrator (k061056)   
2. Comparison with predicate:

Ferritin Reagent

<table><tr><td colspan="3" rowspan="1">SIMILARITIES</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Analyte</td><td colspan="1" rowspan="1">Ferritin</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For in vitro diagnostic use in thequantitative determination offerritin as an aid in the diagnosisof diseases affecting ironmetabolism such ashemochromatosis and irondeficiency anemia</td><td colspan="1" rowspan="1">For quantitaive determinationof ferritin</td></tr><tr><td colspan="1" rowspan="1">Measurement</td><td colspan="1" rowspan="1">Quantitative</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample type</td><td colspan="1" rowspan="1">Serum, plasma</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Format</td><td colspan="1" rowspan="1">Liquid</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Antibodies</td><td colspan="1" rowspan="1">rabbit anti-ferritin antibodies</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Use ofCalibrators</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">DIFFERENCES</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Plasma sampletype</td><td colspan="1" rowspan="1">Lithium heparin and EDTAplasma</td><td colspan="1" rowspan="1">Heparinized plasma</td></tr><tr><td colspan="1" rowspan="1">Reportablerange</td><td colspan="1" rowspan="1">6 - (450-500) ng/mL</td><td colspan="1" rowspan="1">Up to 640 ng/mL</td></tr><tr><td colspan="1" rowspan="1">MethodPrinciple</td><td colspan="1" rowspan="1">Turbidimetric</td><td colspan="1" rowspan="1">Nephelometric</td></tr><tr><td colspan="1" rowspan="1">Reagents</td><td colspan="1" rowspan="1">Two:R1 and R2</td><td colspan="1" rowspan="1">Three:Reagent, Supplementary A andB</td></tr><tr><td colspan="1" rowspan="1">Expected values</td><td colspan="1" rowspan="1">Men: 20 - 250 ng/mLWomen: 10 - 120 ng/mL</td><td colspan="1" rowspan="1">Men: 20 - 290 ng/mLWomen, premenopausal:4.5 - 170 ng/mL,postmenopausal: 24  260ng/mL</td></tr><tr><td colspan="1" rowspan="1">Specificity(differentisoforms)</td><td colspan="1" rowspan="1">Liver: 97.6%Spleen: 80.3%Placenta: 57.5%Heart: 20.9%</td><td colspan="1" rowspan="1">Liver; 94.3%Spleen: 90.4%Placenta: 103.4%Heart: 7.8%</td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">ADVIAChemistry Systems</td><td colspan="1" rowspan="1">BN System</td></tr><tr><td colspan="1" rowspan="1">Reagent on-board stability</td><td colspan="1" rowspan="1">60 days</td><td colspan="1" rowspan="1">28 days</td></tr></table>

Calibrators   

<table><tr><td colspan="3" rowspan="1">SIMILARITIES</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For in vitro diagnostic use in thecalibration of specific assays</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">AnalytesIncluded</td><td colspan="1" rowspan="1">Anti-streptolysinComplement C3 and C4CRPFerritinHaptoglobinIgA, IgG, IgM ,PrealbuminTransferrin</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Form</td><td colspan="1" rowspan="1">Ready-to-use solutions</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Traceability forFerritin</td><td colspan="1" rowspan="1">WHO Third InternationalStandard - NIBSC 94/572</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Matrix</td><td colspan="1" rowspan="1">Buffered base</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Analyte source</td><td colspan="1" rowspan="1">Derived from human source</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Number oflevels</td><td colspan="1" rowspan="1">6 levels (lowest level is a zero-level without any analytes)</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Volume</td><td colspan="1" rowspan="1">1.0 mL each vial</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="3" rowspan="1">DIFFERENCES</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate</td></tr><tr><td colspan="1" rowspan="1">AnalytesIncluded</td><td colspan="1" rowspan="1">Alpha-acid-glycoprotein (AAG),Alpha-1-Antitrypsin,Rheumatoid Factor.</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Instrument</td><td colspan="1" rowspan="1">ADVIAChemistry Systems</td><td colspan="1" rowspan="1">Abbott Spectrum, Architecti2000, Architect i 2000sr;Bayer ADVIA® 1650, 2400,1200;Dade Dimension RXL, AR,Hitachi 704, 717, 911, 917,912, 747;AU800, AU600, AU400,AU2700, AU5400;Synchron CX4, CX5, CX7,LX20;ILAB300, ILAB900,ILAB1800, ILAB600;Cobas Mira, Mira S, Mira Plus</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP05-A2 Evaluation of Precision Performance of Quantitative Measurement Methods   
CLSI EP17-A Protocols for Determination of Limits of Detection and Limits of Quantitation.

L. Test Principle:

In the ADVIA® 1650 Chemistry Ferritin method, a diluted sample reacts with buffer containing latex particles coated with polyclonal rabbit anti-Ferritin antibody. The formation of the antibody-antigen complex results in increased turbidity, which is measured as the amount of light absorbed at $6 5 8 \mathrm { n m }$ . Using a standard curve from the absorbance of calibrators, ferritin concentration of a sample can be determined.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility: Individual serum pools at various concentrations of ferritin and serum-based control materials were tested. Each sample was assayed in duplicate, 2 runs per day, for at least 20 days, yielding 80 observations for each sample. The results are summarized in the table below:

<table><tr><td rowspan=2 colspan=1>Samples</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=2>Within-Run(Repeatability)</td><td rowspan=1 colspan=2>Total(Within-Lab Precision)</td></tr><tr><td rowspan=1 colspan=1>ng/mL</td><td rowspan=1 colspan=1>SD(ng/mL)</td><td rowspan=1 colspan=1>CV (%)</td><td rowspan=1 colspan=1>SD (ng/mL)</td><td rowspan=1 colspan=1>CV (%)</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 1</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>0.44</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>1.04</td><td rowspan=1 colspan=1>8.7</td></tr><tr><td rowspan=1 colspan=1>Serum Control 1</td><td rowspan=1 colspan=1>28.8</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.89</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>Serum Control 2</td><td rowspan=1 colspan=1>185.3</td><td rowspan=1 colspan=1>0.78</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>1.49</td><td rowspan=1 colspan=1>0.8</td></tr><tr><td rowspan=1 colspan=1>Serumn Pool 2</td><td rowspan=1 colspan=1>222.8</td><td rowspan=1 colspan=1>0.87</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.99</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>SerumControl 3</td><td rowspan=1 colspan=1>297.0</td><td rowspan=1 colspan=1>1.06</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.45</td><td rowspan=1 colspan=1>0.8</td></tr><tr><td rowspan=1 colspan=1>Serum Pool 3</td><td rowspan=1 colspan=1>347.0</td><td rowspan=1 colspan=1>3.78</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>4.97</td><td rowspan=1 colspan=1>1.4</td></tr></table>

b. Linearity / assay analytical range:

A high serum pool and a low serum pool were used to prepare nine (9) different ferritin concentrations evenly distributed throughout the assay range. The mean observed ferritin concentration of triplicate measurements at the nine (9) ferritin concentrations was compared with the expected concentration. A weighted least squares linear regression analysis of the linearity data shows that the assay is linear from $6 . 0 \mathrm { n g / m L }$ to 450 to $5 0 0 ~ \mathrm { { n g / m L } }$ with a slope of 1.03 $9 5 \%$ confidence interval (CI): $1 . 0 1 - 1 . 0 5 )$ and y-intercept of -0.03 ( $9 5 \%$ CI: -0.08 − 0.03). Deviation from linearity was $\leq 1 0 \%$ .

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability: The Ferritin values assigned to the calibrators are traceable to the Third International Standard NIBSC 94/572.

Stability of the ADVIA® 1650 Chemistry Ferritin Reagent: Shelf-life stability was determined upon storage of the reagents at $2 { - } 8 \mathrm { { ^ \circ C } }$ for 1, 2, 3, 8 or 13 weeks, 6, 12 or 18 months. On-board stability was evaluated upon storage of the 20- mL wedges in the instrument for 0, 8, 20, 31, 43, 59 or 62 days and 70-mL reagent wedges for 0, 7, 22, 31, 44, 56, 60 and 63 days. Sample recovery at each time point was compared to day 0. Data supports the shelf life stability claim of 18 months at $2 { - } 8 \mathrm { { ^ \circ C } }$ and on-board stability claim of 60 days.

Stability of the ADVIA® Chemistry Liquid Specific Protein Calibrators: Calibrator vials were opened one time and then closed and kept in the refrigerator at $2 { - } 8 \mathrm { { \% } }$ for 29 days. Controls were run in quadruplet as samples using calibration curves generated with the once-opened calibrators and fresh unopened calibrators. Recoveries between the two sets of calibrators were compared. Test results support open-vial stability claim of 28 days. In addition, the data for stability of unopened calibrator vials were provided. Tests results support shelf-life of 24 months at $2 { - } 8 \mathrm { { ^ \circ C } }$ for unopened calibrator vials.

d. Detection limit:

The performance at low levels was evaluated according to CLSI guideline EP17-A. A human serum pool without ferritin and four human serum pools with mean values ranging from $3 . 9 5 \mathrm { n g / m L }$ to $6 . 1 3 \mathrm { n g / m L }$ were tested in six (6) replicates on two instrument systems using two lots of reagents for five (5) days with two (2) runs per day. Results show that the limit of blank, the limit of detection and the limit of quantitation are $1 . 2 ~ \mathrm { n g / m L }$ , $4 . 5 ~ \mathrm { { n g / m L } }$ and $6 . 0 \mathrm { n g / m L }$ , respectively.

e. Analytical specificity:

i. Endogenous Interference: Human serum pools with various concentrations of ferritin were spiked with hemoglobin up to $1 0 0 0 \mathrm { m g / d L }$ , unconjugated bilirubin and conjugated bilirubin up to $6 0 \mathrm { m g / d L }$ , intralipid up to 1000 $\mathrm { m g / d L }$ , and rheumatoid factor up to $2 5 0 0 \mathrm { I U / m L }$ prior to analysis with the ADVIA® 1650 Chemistry Ferritin Reagent. Ferritin concentration observed at each level of an interferent was compared to the observed ferritin concentration of the un-spiked human serum pool. Low level of interference $( < 1 0 \% )$ was observed in the samples with ferritin concentration at approximately $3 0 0 ~ \mathrm { { n g / m L } }$ . Visibly hemolyzed or lipemic samples will produce erroneous results for samples with low ferritin concentrations:

<table><tr><td rowspan=1 colspan=4>ADVIA 1650</td></tr><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>Interferent Level</td><td rowspan=1 colspan=1>Ferritin Level(ng/mL)</td><td rowspan=1 colspan=1>Interference</td></tr><tr><td rowspan=1 colspan=1>Bilirubin</td><td rowspan=1 colspan=1>60 mg/dL (1026 µmol/L)60 mg/dL (1026μmol/L)</td><td rowspan=1 colspan=1>10.9297.7</td><td rowspan=1 colspan=1>NSI*NSI*</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>62.5 mg/dL (0.6 g/L)1000 mg/dL (10.0 g/L)1000) mg/dL (10.0 g/L)</td><td rowspan=1 colspan=1>11.475.2300.4</td><td rowspan=1 colspan=1>44.4%NSI*NSI*</td></tr><tr><td rowspan=1 colspan=1>Lipemia</td><td rowspan=1 colspan=1>250mg/dL (2.8 mmol/L)500mg/dLb (5.7 mmol/L)750 mg/dL (8.5 mmol/L)1000 mg/dL (11.3 mmol g/L)1000mg/dL (11.3 mmol g/L)</td><td rowspan=1 colspan=1>11.311.376.176.1303.4</td><td rowspan=1 colspan=1>NSI*-31.0%NSI*-10.1%NSI*</td></tr><tr><td rowspan=1 colspan=1>RheumatoidFactor</td><td rowspan=1 colspan=1>2500 IU/mL2500 IU/mL</td><td rowspan=1 colspan=1>11.4304.1</td><td rowspan=1 colspan=1>NSI*NSI*</td></tr></table>

$\mathrm { \mathrm { } ^ { * } N S I } = \mathrm { N o t }$ Significant Interference $( < 1 0 \% )$

ii. Specificity of Assay to Ferritin Isoforms: Specificity was tested using a human serum pool with ferritin concentration within normal range, which was spiked with a concentrated solution of a specific ferritin isoform (liver isoform at concentrations up to $2 0 0 ~ \mathrm { { n g / m L } }$ , spleen isoform at concentrations up to $2 0 0 ~ \mathrm { { n g / m L } }$ , heart isoform at the concentrations up to $3 0 0 ~ \mathrm { { n g / m L } }$ , and placenta isoform at concentrations up to $3 0 0 ~ \mathrm { { n g / m L } ) }$ ). The specificity was evaluated by comparing recoveries of spiked sample and un-spiked sample relative to the amount of isoform spiked into a sample. The results are summarized below. The isoform values have clinical relevance regarding the presence of iron overload in certain organs or tissues. It should be noted that the ferritin assay does not identify the tissue isoforms.

<table><tr><td colspan="3" rowspan="1">Liver Isoform</td></tr><tr><td colspan="1" rowspan="1">Amount of isoformspiked, ng/mL</td><td colspan="1" rowspan="1">Observed recovery -Ferritin, ng/mL</td><td colspan="1" rowspan="1">Specificity, %</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">22.8</td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">71.5</td><td colspan="1" rowspan="1">97.4%</td></tr><tr><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">118.9</td><td colspan="1" rowspan="1">96.2%</td></tr><tr><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">221.1</td><td colspan="1" rowspan="1">99.2%</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Average</td><td colspan="1" rowspan="1">97.6%</td></tr><tr><td colspan="3" rowspan="1">Spleen Isoform</td></tr><tr><td colspan="1" rowspan="1">Amount of isoformspiked, ng/mL</td><td colspan="1" rowspan="1">Observed recovery -Ferritin, ng/mL</td><td colspan="1" rowspan="1">Specificity, %</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">85.2</td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1">50</td><td colspan="1" rowspan="1">125.3</td><td colspan="1" rowspan="1">80.1%</td></tr><tr><td colspan="1" rowspan="1">100</td><td colspan="1" rowspan="1">164.8</td><td colspan="1" rowspan="1">79.6%</td></tr><tr><td colspan="1" rowspan="1">200</td><td colspan="1" rowspan="1">247.5</td><td colspan="1" rowspan="1">81.1%</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Average</td><td colspan="1" rowspan="1">80.3%</td></tr><tr><td colspan="3" rowspan="1">Placenta Isoform</td></tr><tr><td colspan="1" rowspan="1">Amount of isoformspiked, ng/mL</td><td colspan="1" rowspan="1">Observed recovery -Ferritin, ng/mL</td><td colspan="1" rowspan="1">Specificity, %</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">19.9</td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">66.0</td><td colspan="1" rowspan="1">61.7%</td></tr><tr><td colspan="1" rowspan="1">225</td><td colspan="1" rowspan="1">147.7</td><td colspan="1" rowspan="1">56.9%</td></tr><tr><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">185.3</td><td colspan="1" rowspan="1">55.2%</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Average</td><td colspan="1" rowspan="1">57.9%</td></tr><tr><td colspan="3" rowspan="1">Heart Isoform</td></tr><tr><td colspan="1" rowspan="1">Amount of isoformspiked, ng/mL</td><td colspan="1" rowspan="1">Observed recovery -Ferritin, ng/mL</td><td colspan="1" rowspan="1">Specificity, %</td></tr><tr><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">21.6</td><td colspan="1" rowspan="1">NA</td></tr><tr><td colspan="1" rowspan="1">75</td><td colspan="1" rowspan="1">37.5</td><td colspan="1" rowspan="1">21.3%</td></tr><tr><td colspan="1" rowspan="1">225</td><td colspan="1" rowspan="1">68.4</td><td colspan="1" rowspan="1">20.8%</td></tr><tr><td colspan="1" rowspan="1">300</td><td colspan="1" rowspan="1">83.0</td><td colspan="1" rowspan="1">20.5%</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Average</td><td colspan="1" rowspan="1">20.9%</td></tr></table>

iii. High Dose Hook Effect: Human serum sample was prepared by spiking a normal serum pool with human liver ferritin to achieve concentrations upto approximately $4 2 , 0 0 0 ~ \mathrm { n g / m L }$ . Serial dilutions were made in saline and all samples were tested. No hook effect was observed up to $4 2 , 0 0 0 ~ \mathrm { n g / m L }$ ferritin.

f. Assay cut-off: See expected values/reference interval

2. Comparison studies:

a. Method comparison with predicate device: Results obtained with forty seven serum samples on the ADVIA 1650 Chemistry Ferritin device and the predicate device, were analyzed using Deming regression and are summarized below.

<table><tr><td>Regression Equation</td></tr><tr><td>y = 1.00x + 0.0</td></tr><tr><td>Slope 95% CI: 0.97 to 1.03; Intercept 95% CI: -3.4 to 3.4</td></tr></table>

$b$ . Matrix comparison:

Forty two matched serum, lithium heparin plasma, and EDTA plasma samples covering the assay range were evaluated on the ADVIA® 1650 Chemistry Ferritin Reagent device. Comparability between serum and plasma was analyzed using Deming regression and results are summarized below:

<table><tr><td>Sample type</td><td>Regression Equation</td></tr><tr><td>Lithium Heparin</td><td>y = 1.00x + 0.1 Slope 95% CI: 0.99 to 1.01 Intercept 95% CI:-0.9 to 1.0</td></tr><tr><td>EDTA</td><td>y = 0.97x - 1.2 Slope 95% CI: 0.96 to 0.99 Intercept 95% CI: -2.6 to 0.2</td></tr></table>

3. Clinical studies:

a. Clinical Sensitivity:   
Not applicable.   
b. Clinical specificity:   
Not applicable.

4. Clinical cut-off: See Expected values/Reference interval.

5. Expected values/Reference interval: The following are suggested reference intervals for this method (from literature): Men: $2 0 { - } 2 5 0 \ \mathrm { n g / m L }$ Women: $1 0 { - } 1 2 0 \ \mathrm { n g / m L }$ Each laboratory should establish its own range.

N. Proposed Labeling: The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion: The submitted information in this premarket notification is complete and supports a substantial equivalence decision.